Articles

SLAS2017 Show Preview: Putting together a ‘Capitol’ event

SLAS2017 will bring a wealth of scientific and other programming to Washington, D.C., in February
Written byJeffrey Bouley
| 9 min read

Society for Laboratory Automation and Screening (SLAS)

SLAS2017

Sixth Annual International Conference and Exhibition

Walter E. Washington Convention Center

Washington, D.C.

Feb. 4-8, 2017

Putting together a ‘Capitol’ event

SLAS2017 will bring a wealth of scientific and other programming to Washington, D.C., in February

As the Society for Laboratory Automation and Screening (SLAS) prepares to bring its Sixth Annual International Conference and Exhibition—more commonly known as SLAS2017—to Washington, D.C., Feb. 4-8, it seems only right to start off our preshow coverage with some of the highlights you can expect at the meeting. And with two conference co-chairs—Dr. Dana Vanderwall, director of biology and preclinical IT at Bristol-Meyers Squibb, and Dr. Marcie Glicksman, chief scientific officer of ORIG3N—who better than they to focus in on what those in drug discovery and development and in diagnostics R&D might find most tasty among the many scientific morsels to be had there?

“I think the agenda is particularly strong in practical applications of technologies that, while starting to mature, are still evolving significantly. For example, there are sessions relevant to phenotypic approaches in three tracks: Assay Development and Screening, Drug Target Strategies and Cellular Technologies; biophysical approaches come up in two tracks; genomic and genetic methods in several tracks,” Vanderwall says. “Many of these talks go beyond the technology development, where leading scientists in the industry share experience and insight from applying the technologies in particular screens or studies. That’s particularly useful when you’re trying to bring a new approach in-house and apply it for drug discovery—the more you can learn from others the sooner you are able to leverage a new technology or methodology to do something useful.”

“The Data and Analysis track is another where there are a number of sessions with practical applications, and where the sessions evolve significantly each year to align with the most significant challenges we face with managing and leveraging data,” he adds. “At the end of the day, the advances in screening and automation result in an increase in both the volume and complexity of data being generated. Topics that deal with tools or approaches focused on workflows, ease of access, use and sharing data, specific aspects of collaboration can all be useful to getting more of your organization’s data and technology investments.”

For her part, Glicksman says, “I am particularly excited about the regenerative medicine symposium I have organized with [Dr. G. Sitta Sittampalam] because this is a rapidly advancing area in drug discovery. The 21st Century Cures Act that was just passed by Congress and signed into law by President Obama has a new provision to fast-track developing new therapies in the regenerative medicine area.”

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Published In

Volume 13 - Issue 1 | January 2017

January 2017

January 2017 Issue

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A scientist in a white lab coat looking into a microscope in a brightly lit modern laboratory.
Learn how developmental and reproductive toxicology study selection supports regulatory decision-making and generates meaningful nonclinical safety data.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue